Chong Kun Dang Pharmaceutical Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chong Kun Dang Pharmaceutical Corp.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To ‘Follow Science’ In Vaccine Trials
The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.
As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.
CureVac starts mRNA vaccine trial, Interprotein uses AI in drug discovery and South Korea's Chong Kun and Hanmi make clinical progress.
- Generic Drugs